Hepatitis C News

PARIS — Two real-world studies presented at the International Liver Congress 2018 confirmed the efficacy and safety of Mavyret in Italy and Germany even in the face of multiple comorbidities.

PARIS — Treating hepatitis C virus in the early stage of disease saves money in drug and medical costs while lowering risk for decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver-related death, according to a presentation at the International Liver Congress 2018.

PARIS — Beginning Wednesday, April 11, Healio Gastroenterology and Liver Disease will provide live coverage from the International Liver Congress 2018.

Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially hepatocellular carcinoma. Recent studies have focused on defining liver cancer risks related to HCV progression and the rates of liver cancer after HCV clearance with new direct-acting antivirals.

A novel point-of-care test for hepatitis C meets the recent Foundation for Innovation in New Diagnostics and World Health Organization’s Target Product Profile for HCV decentralized testing in low-income and middle-income countries, according to a recently published study.

A Colorado hospital has warned patients they may have been exposed to serious infections through improperly sterilized surgical instruments, according to state health officials.

While hepatitis C treatment rates have improved since the introduction of direct-acting antivirals, researchers found that overall treatment rates in a large, ethnically diverse cohort were less than 20% and lowest among Hispanic patients and those with Medicaid or indigent care, according to a recently published study.

Undiagnosed hepatitis C was more common than undiagnosed HIV in a survey of patients admitted to a New York emergency department, according to a recently published study.

According to researchers, more than 6% of baby boomers tested positive for hepatitis C virus antibodies during a recent 7-month period at a small-city New Jersey ED — twice as high as the CDC estimate for the high-risk group.

Sofosbuvir plus ribavirin with or without pegylated interferon was safe and effective in Chinese patients with hepatitis C genotypes 1, 2, 3 and 6, regardless of treatment experience, according to recently published data.